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Summary
 
To determine the role of CD8
 
1
 
 T cells in controlling simian immunodeficiency virus (SIV)
replication in vivo, we examined the effect of depleting this cell population using an anti-CD8
monoclonal antibody, OKT8F. There was on average a 99.9% reduction of CD8 cells in pe-
ripheral blood in six infected 
 
Macaca mulatta
 
 treated with OKT8F. The apparent CD8 deple-
tion started 1 h after antibody administration, and low CD8 levels were maintained until day 8.
An increase in plasma viremia of one to three orders of magnitude was observed in five of the
six macaques. The injection of a control antibody to an infected macaque did not induce a sus-
tained viral load increase, nor did it significantly reduce the number of CD8
 
1
 
 T cells. These re-
sults demonstrate that CD8 cells play a crucial role in suppressing SIV replication in vivo.
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S
 
ince the original demonstration that attenuated simian
immunodeficiency virus (SIV)
 
1
 
 could confer protection
against a wild-type virus in rhesus macaques (1), a better
understanding of the protective mechanism(s) has been
sought. Although CTL (2), Th cell (3), and neutralizing
antibody (1) responses have been found in these protected
macaques, the correlates of protective immunity remain
undetermined. Antibody responses to SIV gp130 and p24
antigens do not correlate with protection (4). The role of
neutralizing antibodies in protection is questionable (4, 5).
Although the protective role of Th cells has been impli-
cated in humans by a correlative study (6), it has neither
been shown in the macaque model, nor has its importance
been documented in vivo. CD8
 
1
 
 CTLs have been shown
to protect against a variety of viral infections in animals (7)
and humans (8–11). Therefore, it is possible that such a re-
sponse will afford protection against retroviral infections as
well. Several lines of experimental evidence support this
supposition. First, a strong CTL response has been impli-
cated in suppressing HIV infection in humans (12–16) and
SIV infection in macaques (17, 18). Second, there is an in-
verse correlation between viral load and virus-specific CTL
precursor frequencies in HIV-infected patients (19, 20),
and between the level of plasma viremia and the number of
effector CTLs (21). Third, a selective reduction of HIV-
specific CTL precursors occurs in the advanced stages of
HIV infection (22, 23). The mechanisms of CD8
 
1
 
 T cell–
mediated protection have been previously demonstrated,
mostly in vitro. CD8
 
1
 
 T cells may be able to control HIV
or SIV replication by either lysing the HIV-infected cell di-
rectly or by the production of 
 
b
 
-chemokines or other as
yet undefined viral inhibitory factors (24–27).
Several attempts have been made to examine the in vivo
role of CD8
 
1
 
 T cells in SIV infection, but no consensus has
been reached. To elucidate the mechanisms of protective
immunity, Stebbings et al. (28) immunized macaques with
an attenuated virus, SIVmac32H (pC8). They then partially
depleted CD8
 
1
 
 T cells from these macaques, and chal-
lenged each with a wild-type pathogenic SIVmac32H
(pJ5). The wild-type virus did not replicate in these vacci-
nated macaques even after their CD8
 
1
 
 T cells were largely
eliminated. Thus, protection was not abrogated by a partial
lowering of the CD8
 
1
 
 T cells. In another experiment per-
 
1
 
Abbreviation used in this paper:
 
 SIV, simian immunodeficiency virus. 
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formed by Matano et al. (29), naive macaques were first de-
pleted of CD8
 
1
 
 T cells, then challenged with a chimeric
SIV/HIV, also known as SHIV. Higher viral loads and a
more profound depletion of CD4
 
1
 
 T cells were found in
these macaques than in controls, suggesting that CD8
 
1
 
 T
cells are important in the control of SIV replication during
primary infection.
Viral load in plasma has been shown to be a major prog-
nostic marker for disease progression in HIV-infected hu-
mans (30). We hypothesize that specific immune responses
mediated by CD8
 
1
 
 T cells play a key role in suppressing
virus replication. In the current study, we investigated the in
vivo role of CD8
 
1
 
 T cells in SIV-infected rhesus macaques
that have reached a steady state of viremia. CD8
 
1
 
 T cells
were depleted by an anti-CD8 antibody, and the virologic
and immunologic consequences were examined. We found
that the depletion of CD8
 
1
 
 T cells in infected macaques re-
sulted in large increases in plasma viremia, thereby demon-
strating that CD8
 
1
 
 T cells must play a major role in the
control of chronic SIV replication in vivo.
 
Materials and Methods
 
Animals Used in the Study.
 
Seven SIV-infected and one unin-
fected rhesus macaque (
 
Macaca mulatta
 
) were used (see Table I).
Six infected and one uninfected animal were given OKT8F (gift
from R. Knowles, R.W. Johnson Pharmaceutical Research Insti-
tute, Raritan, NJ). One other infected macaque received an iso-
type-matched (IgG2a) control antibody, P1.17 (TIB-10; Am-
erican Type Culture Collection). All animal protocols were
approved by the Institutional Animal Care and Use Committee at
the Tulane Regional Primate Research Center.
 
Depletion of CD8
 
1
 
 T Cells In Vivo.
 
Macaques were first anes-
thetized with 10 mg/kg ketamine-HCl, then given bolus injec-
tions of OKT8F or P1.17 at 2 mg/kg daily for three consecutive
days. 5–6 ml of peripheral blood was obtained frequently before
and at various time points after antibody injection from each
monkey.
 
Phenotypic Analysis of the T Cell Subsets.
 
Four-color flow cy-
tometric analyses of whole blood samples were performed to
monitor changes in T cell populations. In brief, 100 
 
m
 
l aliquots of
whole blood were incubated with respective antibodies for 30
min at 4
 
8
 
C, then washed twice with PBS containing 2% FCS.
The red blood cells were first lysed with FACS Lysing Solution
 
®
 
(Becton Dickinson), and washed away. Ki67-FITC (Immuno-
tech) or an FITC-conjugated control antibody was then added to
respective tubes for intracellular staining for 30 min at 4
 
8
 
C, fol-
lowed by further washes and resuspension in 2% formaldehyde
(Tousimis Research Corp.) before analysis on a FACSCalibur™
flow cytometer (Becton Dickinson). The antibodies used in the
study were RhCD3-FITC (Immunotech), CD3-PE (PharMin-
gen), CD4-allophycocyanin (APC; Exlpha), CD8–peridinine
chlorophyll protein (PerCP; Becton Dickinson), CD8
 
b
 
-PE (Im-
munotech), CD45RA-FITC (Becton Dickinson), CD69-PE
(Becton Dickinson), and control antibodies IgG1-FITC, IgG1-
PE, IgG1-PerCP, and IgG1-APC (Caltag Laboratories).
 
Quantifying Plasma Load of SIV by Real-time PCR.
 
To mea-
sure the viral load of infected monkeys, plasma was separated
from whole blood collected in EDTA-containing tubes. Plasma
samples were initially spun at 5,000 rpm for 10 min to remove
any cells. About 600 
 
m
 
l to 1 ml of plasma was ultracentrifuged at
 
17,000 rpm for 60 min at 4
 
8
 
C. Supernatant was removed leaving
 
z
 
140 
 
m
 
l of plasma and a viral pellet. Viral RNA was purified us-
ing the QIAamp viral RNA kit (QIAGEN Inc.). Reverse tran-
scription of viral RNA was then performed in 96-well plates.
Each 30-
 
m
 
l reaction contained 10 
 
m
 
l of viral RNA, 1
 
3
 
 Taqman
Buffer A (Perkin-Elmer), 5 mM MgCl
 
2
 
, 2.5 
 
m
 
M random hexam-
ers (Perkin-Elmer), 0.5 mM each of dATP, dCTP, dGTP, and
dTTP, 20 U RNAsin (Promega), and 20 U Moloney murine
leukemia virus reverse transcriptase (Superscript; GIBCO BRL).
One round of reverse transcription (25
 
8
 
C for 15 min, 42
 
8
 
C for
40 min, 75
 
8
 
C for 5 min) was performed.
To quantify the copy number of viral RNA, a molecular bea-
con was used in combination with real-time PCR. This method
of detection using molecular beacons (31, 32) and a fluorescence
detector system (33) has been described previously. Each 50-
 
m
 
l
reaction contained 30 
 
m
 
l of cDNA from the reverse transcription
reaction, and the final concentration of each component was as
follows: 0.4
 
3
 
 PCR buffer II, 0.6
 
3
 
 Taqman buffer A, 3.5 mM
MgCl
 
2
 
, 0.4 pmol/
 
m
 
l of molecular beacon, 0.4 pmol/
 
m
 
l of each
primer, 1.25 U of AmpliTaq Gold DNA polymerase (Perkin-
Elmer). The primers used were SL03 (5
 
9
 
-AGGGAAGAAAGCA-
GATGAATTA-3
 
9
 
) and SL04 (5
 
9
 
-GTTTCACTTTCTCTTCTG-
CGT-3
 
9
 
). The molecular beacon was designed to recognize a region
within SIV gag (5
 
9
 
-FAM-CGCTGGAGAACAAAGAAGGAT-
GTCACAGCG-DABCYL-3
 
9
 
) where FAM (6-carboxyfluores-
cein) serves as the reporter fluorochrome and DABCYL (4
 
9
 
 di-
methylaminophenylazo benzoic acid) the quencher. One cycle of
denaturation (95
 
8
 
C for 10 min) was performed, followed by 45
cycles of amplification (95
 
8
 
C for 15 s, 55
 
8
 
C for 30 s, 72
 
8
 
C for
30 s). The PCR reaction was carried out in an ABI 7700 PRISM
spectrofluorometric thermal cycler (Applied Biosystems, Inc.)
that monitors changes in the fluorescence spectrum of each reac-
tion tube, while simultaneously carrying out programmed tem-
perature cycles.
The method of quantifying viral load was adapted from a pre-
vious report (33) with some modifications. For each run, a stan-
dard curve was generated from duplicate samples of purified
RNA transcripts ranging from 10
 
6
 
 copies to 50 copy equivalents
per reaction (using serial log dilutions in RNase-free water). Each
test specimen was reverse transcribed and amplified in duplicate.
A third reaction was processed and amplified without the addi-
tion of reverse transcriptase to control for potential DNA con-
tamination. Copy numbers were calculated by interpolation of
the experimentally determined threshold cycle as described previ-
ously (33). The lower limit of detection was 50 copy equivalents
per reaction with a linear dynamic range of 
 
.
 
5 logs. When ad-
justed for the various dilution effects, this results in a sensitivity of
 
z
 
400 RNA copies per ml of plasma. The mean of replicate sam-
ples was reported.
 
Results
 
Eight macaques were included in this study. Seven were
SIV-infected, and one was uninfected. The macaques had
been inoculated with either SIVmac251 or 239 between 1
and 4 yr before these experiments (Table I). The effects of
administration of either a murine anti-CD8 mAb, OKT8F,
or an isotype-matched control antibody, P1.17, on lym-
phocyte subsets and plasma viremia were examined.
 
Inverse Association between CD8
 
1
 
 T Cell Count and Plasma
Viremia after OKT8F Injection.
 
Six SIV-infected macaques
were given OKT8F (2 mg/kg) intravenously as a bolus in- 
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jection daily for three consecutive days. No febrile episodes
or adverse events were observed after each antibody ad-
ministration. Blood was taken before and at various time
points after OKT8F injection. After the third antibody in-
jection, there was an average of 99.9% reduction of CD8
 
1
 
T cells in peripheral blood (from a mean of 1,139 to 1/
 
m
 
l).
In five of six macaques, the depletion was apparent as early
as 1 h after the first dose of OKT8F. The number of CD8
 
1
 
T cells stayed low for 8–10 d, then began to recover in all
six animals (Fig. 1). To ensure that the disappearance of
CD8
 
1
 
 T cells from the blood was genuine, the difference
between the percentage of CD3
 
1
 
 T cells and that of CD4
 
1
 
T cells was determined as a measurement of the percentage
of CD8
 
1
 
 T cells. Results showed that this difference was
also substantially decreased in all animals (from a mean of
43 to 13%) after the administration of OKT8F.
The effect of CD8
 
1
 
 T cell depletion on plasma viremia
was dramatic. An immediate increase in viral load in five of
six macaques (AT-02, AT-22, AR-68, AR-71, and AR-
93) was noted. The magnitude of the peak viral load in-
crease varied from 20- to 2,500-fold (Fig. 1, and Table I).
One macaque, AR-90, had a viral load below the level of
detection initially (
 
,
 
400 SIV RNA copies/ml) and re-
mained so during the course of the experiment (Fig. 1).
The rise and fall of viremia were temporally associated with
the drop and then rebound of CD8
 
1
 
 T cell counts during
the first 2 wk. After CD8
 
1
 
 T cell counts recovered to pre-
treatment levels, the viral loads also returned to near base-
line levels in four of five macaques that had detectable vire-
mia (Fig. 1). The second rise in plasma viremia on day 36
in AR-68 is unexplained. In contrast, the injection of a
control antibody, P1.17, to SIV-infected macaque AT-48
caused only a minor perturbation of CD8
 
1
 
 T cells and a
relatively modest elevation of plasma viremia transiently
(Table I, and Fig. 1).
 
The Impact of OKT8F on Other Lymphocyte Subsets.
 
Consistent with a depletion of CD8
 
1
 
 T cells, the total
number of CD3
 
1
 
 T lymphocytes was also reduced in all
macaques receiving OKT8F (Fig. 2). The CD3 counts
stayed lower than the baseline levels for 
 
z
 
8–10 d, then be-
gan to recover in a majority of the animals (AT-22, AT-03,
AT-02, AR-68, and AR-93), following kinetics very simi-
lar to those of CD8
 
1
 
 T cells. Macaques AR-71 and AR-90
had a slower rate of recovery.
The injection of OKT8F also had effects on CD4
 
1
 
 T
cells in the six SIV-infected macaques. A 51% reduction of
the absolute number of CD4
 
1
 
 T cells occurred, most no-
ticeably on day 1 (from a mean of 505 to 250/
 
m
 
l). This was
followed by a period of rapid fluctuation in cell counts over
the next few days before the CD4
 
1
 
 T cell numbers recov-
ered to pretreatment levels by day 15 in most macaques
(Fig. 2). Again, AR-71 and AR-90 had a slower rate of re-
covery. The reduction in the number of CD4
 
1
 
 T cells
could be accounted for by either an increased destruction
of CD4
 
1
 
 T cells as a consequence of elevated viral replica-
tion, or OKT8F-mediated cellular activation followed by
apoptosis. To distinguish between these two possibilities,
OKT8F was given to an uninfected macaque, AT-03. As
expected, dramatic CD8 depletion (100%) was observed in
the blood of this animal (Fig. 1). But the injection of this an-
tibody also led to a 50% reduction of CD4
 
1
 
 T cells, similar
to that observed in infected macaques. Therefore, the partial
CD4 depletion is unlikely to be caused by SIV replication.
If antibody injection can lead to nonspecific cellular acti-
vation, then the observed viral load increase may have re-
sulted from elevated viral production due to an expansion
of activated CD4 target cells, rather than a simple loss of vi-
ral suppression by CD8
 
1 T cells. To examine this possibil-
ity, an isotype-matched control antibody, P1.17, was given
to an SIV-infected macaque, AT-48. P1.17 injection did
Table I. Characteristics of the Macaques
Macaques
Pretreatment and posttreatment values
Antibody given Plasma RNA CD4/ml CD8/ml Inoculation
Type Dose Pre- Peak Pre- Day 3 Pre- Day 3 Virus
Duration of
infection
mg/kg copies/ml mo
Controls
AT-03 OKT8F 2 – – 1,698 856 1,086 0 None –
AT-48 P1.17 2 1.3 3 105 3.5 3 105 251 186 213 210 SIVmac251 16
Tests
AT-02 OKT8F 2 8 3 104 2 3 108 903 238 3,379 4 SIVmac251 15
AT-22 OKT8F 2 1 3 105 2 3 106 112 94 285 0 SIVmac239 34
AR-68 OKT8F 2 ,4 3 102 2 3 105 513 378 944 0 SIVmac251 23
AR-71 OKT8F 2 ,4 3 102 1 3 105 707 353 834 0 SIVmac251 25
AR-90 OKT8F 2 ,4 3 102 ,4 3 102 630 342 458 1 SIVmac251 50
AR-93 OKT8F 2 6 3 104 1 3 107 166 95 989 0 SIVmac251 12994 Suppression of SIV In Vivo by CD81 T Cells
not deplete CD81 T cells, but fluctuations in CD4 and
CD8 cells were observed (Figs. 1 and 2). On the other
hand, the viral load fluctuated, with a modest peak increase
of only threefold, which then decreased to levels below the
baseline value (Fig. 1, and Table I). Thus, the stimulation
caused by large doses of a murine mAb is not sufficient to
explain the dramatic increases in plasma viremia observed
after OKT8F injection.
The observed increase in viremia after CD81 T cell de-
pletion could either be a reflection of diminishing viral
control by CD81 T cells, or an augmentation of viral pro-
duction due to increased availability of CD41 target cells,
or both. Because activated or proliferating CD41 T cells
are better target cells for SIV infections (34), CD41 T cells
were examined by flow cytometry for the expression of a
nuclear antigen, Ki67, that is indicative of cells in the pro-
cess of cycling (not in G0 [35]). Results from these experi-
ments showed that there was an initial reduction in the ab-
solute number of Ki671CD41 cells after the first dose of
OKT8F, and a later recovery during the period of CD4 cell
Figure 1. Temporal association between CD8 decline and viral load increase. The impact of OKT8 (dark blue arrows) on viral load (red circles) and
CD81 T cell counts (green squares) was examined in six chronically infected macaques (AT-02, AT-22, AR-68, AR-71, AR-90, and AR-93) and one
uninfected animal (AT-03). The injection of a control antibody (light blue arrows), P1.17, to an infected macaque (AT-48) is also shown. The dotted
line denotes the level of sensitivity of the viral load assay.
Figure 2. The impact of OKT8F, or the control antibody, on the total number of CD31 (orange squares), CD41 (blue triangles), and CD41Ki671
(purple circles) cells.995 Jin et al.
rebound (Fig. 2). On average, there was only a threefold
increase (from 46 to 150/ml) in the number of CD41 T
cells expressing Ki67 in SIV-infected animals and less than
a threefold increase in the SIV-negative monkey, AT-03, a
level insufficient to account for the increase in plasma vire-
mia. The first peak of Ki671CD41 T cells appeared around
day 3 in six of seven macaques receiving OKT8F (AT-02,
AT-22, AT-68, AR-71, AR-90, and AR-93). The same
was true for the macaque (AT-48) that received the iso-
type-matched control antibody (Fig. 2). In several ma-
caques (AT-02, AT-03, AT-22, and AR-68), there was a
pronounced second peak of Ki671CD41 T cells on days
12–24, coincident with the timing of CD81 T cell regen-
eration. The precise mechanism responsible for this second
peak is unclear. However, since it appeared much later than
the peak of plasma viremia, this second wave of Ki671CD41
cell rise is unlikely to have contributed to the one- to three-
log increases in plasma viremia observed earlier.
Theoretical Predictions on the Possible Mechanisms Responsi-
ble for the Observed Increase in Plasma Viremia after CD81 T
Cell Depletion in Infected Macaques. Several mechanisms could
be responsible for the observed increase in viral load. The
removal of CD81 CTLs could increase the life span of pro-
ductively infected cells, leading to greater virion produc-
tion. Alternatively, the depletion of CD81 T cells may re-
duce the production of b-chemokines, which block the
entry of certain virions into target cells (26), or of inhibi-
tory factors that suppress viral transcription, thereby in-
creasing virion output from productively infected cells (36).
To assess these possibilities, we used a standard model of
HIV-1 dynamics (37, 38) adjusted to account for the
eclipse phase of the viral life cycle (39, and our unpublished
observations). Specifically, we used a model involving tar-
get cells, T, productively infected cells, T*, virus, V, and t
which defines the number of days required for a generation
of HIV in vivo. In addition, the following parameters are
introduced: (a) the death rate of infected cells, d; (b) the vi-
ral production rate, p; and (c) the infection rate constant, k.
Based on these parameters, the model could be described
by the following equations: (1) dT/dt 5 l – dTT – kVT, (2)
dT*/dt 5 E k(t 2 t)V(t 2 t)T(t 2 t)dt – dT*, and (3) dV/dt 5
pT* 2 cV. 
The delay t is given by a gamma distribution with a peak
at 1.5 d and an SD of 0.31 d (39). Parameters initially cho-
sen were d 5 0.5 d21, c 5 30 d21 (reference 39, and our
unpublished observations), p 5 100 d21, and dT 5 0.01
d21. The parameters l and k were chosen to yield a steady
state consistent with the measured baseline viral load and
CD41 T cell count. Giving anti-CD8 antibody was as-
sumed to perturb the steady state of the system such that
the parameter being examined changed immediately. The-
oretical curves were then generated using nonlinear least-
squares regression to find the new value of d, k, or p that
gave the best fit to the data.
A representative analysis of the experimental data on two
macaques is shown in Fig. 3, where for AT-22, l 5 21.1
d21 and k 5 1.33 3 1023 ml21d21, whereas for AR-93, l 5
10.4 d21 and k 5 9.0 3 1024 ml21d21. To mimic the loss of
CTL killing, the death rate of productively infected T cells,
d, was decreased. However, setting d 5 0 as the most ex-
treme case did not cause the viral load to increase as rapidly
as observed experimentally. Similarly, increasing the infec-
tion rate constant, k, to mimic the loss of b-chemokines
from CD81 T cells, could not explain the rapid increase in
viral load seen during the first 24 h, since removing a block
on infection has no effect on plasma viral load until after
the eclipse phase of the viral life cycle (37). Finally, remov-
ing inhibitory factors on viral transcription is equivalent to
increasing p, the rate of virion production by productively
infected cells. As shown in the two examples in Fig. 3, this
gives a rapid increase in plasma virus, followed by a plateau
period during which newly produced virions go on to in-
fect cells and traverse the eclipse phase. It is evident from
these preliminary theoretical analyses that neither changes
in p or k fit the observed data particularly well, but an in-
crease in p provides a better fit than an increase in k.
Discussion
The role of CD81 T cells in the control of SIV replica-
tion in vivo awaits experimental confirmation. Here, we
examined their importance by depleting these cells with an
anti-CD8 mAb, OKT8F, and by following the subsequent
virologic and immunologic changes. Although the extent
of CD81 T cell depletion was not examined in lymphoid
Figure 3. Plasma viral load data from two monkeys together with the-
oretical predictions based on a standard model of HIV-1 dynamics. The
theoretical predictions model changes in the death rate of infected cells, d,
the viral production rate, p, or the infection rate constant, k, after anti-
CD8 treatment. The theoretical curves shown were generated using non-
linear least-squares regression to find the new value of d, k, or p that gave
the best fit to the data.996 Suppression of SIV In Vivo by CD81 T Cells
tissues in our study, we found that depleting such T cells in
peripheral blood led to a peak viral load increase of one to
three orders of magnitude in five of six macaques studied.
These results demonstrate that CD81 T cells, at a mini-
mum, must play a major role in the control of SIV replica-
tion during chronic infection. If OKT8F administration
did not result in complete CD81 T cell depletion in lym-
phoid tissues in our experiment, then the role of these cells
in inhibiting viral replication in vivo would be even more
significant than what was observed here. Thus, we concur
with the conclusion drawn by Matano et al.  (29), who
studied the effect of CD8 depletion in primary SHIV infec-
tion.
The depletion of CD81 T cells by OKT8F was not un-
expected; however, the speed at which CD81 T cells dis-
appeared from blood was surprising. Nevertheless, the ki-
netics of CD8 depletion observed in our experiments is
consistent with previous depletion experiments done by
others (28, 29). Likewise, the OKT4 antibody cleared
CD41 T cells from peripheral blood within 10 min of in-
jection in rhesus monkeys (40). The OKT3 antibody also
depleted most of the peripheral T lymphocytes within 1 h
after administration to humans (41).
Several mechanisms may be responsible for the observed
depletion of CD81 T cells from the blood. First, the bind-
ing of OKT8F to CD8 molecules on cells may have led
to complement-mediated cytolysis. Second, OKT8F may
have only masked the epitope recognized by the staining
anti-CD8 antibody, resulting in an artificially low number
of CD81 T cells. Third, there may have been an increased
CD8 endocytosis after binding by OKT8F, thereby lower-
ing surface CD8 expression without cellular depletion. Fi-
nally, there may have been a preferential trapping of anti-
body-bound CD81 T cells in lymph tissues, leading to an
apparent depletion of such cells in the circulation. To ad-
dress the second and third possibilities above, we examined
the difference in the number of CD31 and CD41 T cells.
This difference declined in parallel with the number of
CD81 T cells measured directly, showing that there is a
genuine depletion of CD81 T cells in blood. Further ex-
periments are necessary to examine the possibility of trap-
ping of CD8 cells in lymphoid tissues after OKT8F injec-
tion. However, if the CD81 T cells were trapped in the
lymph nodes, where most of the viral replication takes
place, they were probably nonfunctional given the substan-
tial rise in plasma viremia. Irrespective of the underlying
mechanism, the injection of OKT8F appears to have se-
verely impacted the CD81 T cells as to cause a dramatic in-
crease in virus replication. However, it is still formally pos-
sible that the loss of control of viral replication is due partly
to the elimination of NK cells that express CD8 on their
surface.
Several different mechanisms could potentially be re-
sponsible for the increase in viral load. The removal of
CD81 CTLs could increase the life span of productively
infected cells, leading to greater virion production. Alter-
natively, the depletion of CD81 T cells may reduce the
production of factors, such as b-chemokines, that block the
entry of certain virions into target cells (26), or of inhibi-
tory factors that suppress viral transcription, thereby reduc-
ing virion output from productively infected cells (36). To
quantitatively evaluate these hypotheses, we used a standard
model of HIV-1 dynamics (37, 38) adjusted to account for
the eclipse phase of the viral life cycle (39, and our unpub-
lished observations). For each monkey, a set of parameters
was determined that corresponded to the animal being in a
steady state with the measured baseline viral load and
CD41 T cell count. To mimic the loss of CTL killing, the
death rate of productively infected T cells, d, was de-
creased. Even lowering d to 0 as the most extreme case did
not cause the viral load to increase as rapidly as observed.
Similarly, increasing the infection rate constant, k, to
mimic the loss of b-chemokines from CD81 T cells, could
not explain the rapid increase in viral load seen during the
first 24 h (Fig. 3). Finally, removing inhibitory factors on
viral transcription (increasing p) gives a better fit to the
data. Thus, the rapid rise in plasma viremia over the first
2–3 d is more consistent with a higher virus production
rate than a higher infection rate. Moreover, even a maxi-
mal decrease in d fails to give a good fit to the data, sug-
gesting that decreased cytotoxic killing is not the primary
mechanism responsible for the increased viremia. Overall,
these conclusions on the mechanism of virus inhibition by
CD81 T cells should be viewed as preliminary and must be
addressed in greater detail in future experiments.
The depletion of CD81 T cells was accompanied by re-
duction in the CD41 T cells in all animals receiving
OKT8F. Several possible explanations might be consid-
ered. There may have been increased destruction of CD41
T cells due to rapid rise in SIV replication after OKT8F in-
fection. However, when the same antibody was given to an
uninfected macaque (AT-03), a similar magnitude of de-
pletion of CD41 T cells was also observed. Therefore, SIV
is unlikely to have contributed significantly to this phe-
nomenon. In agreement with our findings, it was observed
in a previous study that treatment with anti-CD8 antibody
also resulted in lowering of B cells and CD41 T cells (42).
It is worth noting that the injection of OKT3 also led to a
depletion of non-T cells, such as B cells and NK cells, in
humans (41). Thus, another explanation is that OKT8F in-
jection may be equivalent to a large dose of foreign anti-
gen, activating numerous cell types, including CD41 T
cells that later undergo activation-induced apoptosis. Fi-
nally, we have noted that there are greater numbers of lym-
phocytes (up to 14%) that coexpress CD4 and CD8 in SIV-
infected macaques (our unpublished observations). The
elimination of such cells by OKT8F may contribute to the
lowering of CD41 T cell counts, although they are numer-
ically insufficient to be the sole mechanism. Further studies
are necessary to understand the indirect impact on the
CD41 T cell population.
In summary, we have demonstrated that CD81 T cells
do play a major role in controlling SIV in vivo. Therefore,
we suggest that in the development of SIV or HIV vac-
cines, a stronger emphasis be placed on inducing specific
CD81 T cell responses.997 Jin et al.
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